

REFERENCES

1. **Apushkin MA, Fishman GA, Janowicz MJ.** Monitoring cystoid macular edema by OCT In patients with retinitis pigmentosa. *Ophthalmology* 2004; 111:1899-1904.
2. **Boppart SA, Bouma BE, Pitris C, et al.** In vivo cellular optical coherence tomography imaging. *Nat Med.* 1998;4:861-865.
3. **Born AJ, Tripathi RC and Tripathi BJ.** “The retina” in Wolff’s anatomy of the eye and orbit. Chapman & Hall, 2-6 boundary row, London, UK. 6th ed., 1997; Ch.14, 444-488.
4. **Bressler SB, Ferris FL, Davis MD, et al.** A simple clinical scale for estimating the risk of age-related macular degeneration progression. *Invest Ophthalmol Vis Sci* 2005;46:E-Abstract.
5. **Brown DJ, Mc Owen, Bowen RM, and Marah TL.** Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. *Ophthalmology* 2004;111: 712–715.
6. **Chan A, Duker JS, Schuman JS, and Fujimoto JG.** Stage 0 Macular Holes Observations by Optical Coherence Tomography. *Ophthalmology* 2004;111:2027-2032.

7. **Chew EY, Sperduto RD, Hiller R, et al.** Clinical course of macular holes: the Eye Disease Case-Control Study. *Arch Ophthalmol* 1999;117:242-246.
8. **Chung H, Hwang JU, Kim JG, Yoon YH.** OCT in the diagnosis and monitoring of cystoid macular edema by OCT in patients with retinitis pigmentosa. *Retina* 2006;26:922-927.
9. **Costa RA, Farah ME, Cardillo JA, et al.** Immediate indocyanine green angiography and OCT evaluation after photodynamic therapy for sub foveal chroidal neovascularisation. *Retina* 2003; 23:159-165.
10. **De Bustros S, and Wendel RT.** Vitrectomy for impending and full-thickness macular holes *Int Ophthalmol Clin*; 1992; 32: 139-152.
11. **De Bustros S.** Vitrectomy for Prevention of Macular Hole Study Group. Vitrectomy for prevention of macular holes: results of a randomized multicenter clinical trial. *Ophthalmology* 1994; 101:1055-1059, discussion 1060.
12. **Dick JS, Jampol LM, Haller JA.** Macular edema. In : Ryan SJ, Schachat AP, eds. *Retina*. St Louis, Mo: Mosby, 2001: 967 – 981.
13. **Drexler W, Sattmann H, Hermann B, et al,** Enhanced visualization of macular pathology with the use of ultrahigh-resolution- optical coherence tomography. *Arch Ophthalmol* 2003; 121: 695- 706.

14. **Duker JS.** Interpretation OCT: Pearls in Age-Related Macular Degeneration, Highlights of ophthalmology 2006; 34: 9-11.
15. **El-Said EM. And Sabry D.** Early diagnosis of Diabetic macular edema: fluorescein angiography versus Optical coherence tomography. Bulletin of ophthalmology, 2006; Vol. 99, No. 4, P. 465-470.
16. **Fujimoto JG, De Silvestri S, Ippen EP, et al:** Femtosecond optical ranging in biological system. Opt. Lett. 1986; 11: 150-152.
17. **Gass JD.** Reappraisal of biomicroscopic classification of stages of development of a macular hole. Am J Ophthalmol 1995;119:752-759.
18. **Gass JD.** Idiopathic senile macular hole: its early stages and pathogenesis: Arch. Ophthalmolo. 1988; 106:629-39.
19. **Gaudric A, Haouchine B, Massin P et al.,** Macular hole formation: new data provided by optical coherence tomography. Arch Ophthalmol 1999;117:744-51.
20. **Gonzales CR.** Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with Pegaptanib sodium: an exploratory analysis. Retina 2005; 63:331-335.
21. **Gross JG.** Carolina Retina Center Columbia, South Carolina, U.S.A. ,Interpretation of OCT; Pearls in Macular Holes. Highlights Of Ophthalmology 2006; 34:16-19.

22. **Gross JG, Emerson et al.,** optical coherence tomography finding during Pegaptanib therapy for neovascular age-related macular degeneration. *Retina* 2007;27:724-729.
23. **Gupta V, Gupta A, Dogra R.** Atlas OCT of macular disease. 2004; 3 – 17.
24. **Hee MR., Izatt JA., Swanson EA., Huang D, Schuman JS., Lin CP., Puliafito CA. and Fujimoto JG.** Optical coherence tomography of human retina. *Arch. Ophthalmolo.* 1995;113: 325-332.
25. **Hee MR, Puliafito CA, Duker JS, Reichel E, Cocker JG, Wilkins JR., Schuman JS., Swanson EA. and Fujimoto JG.** Topography of diabetic macular oedema with optical coherence tomography. *Ophthalmol.* 1998; 105: 360-370.
26. **Hee MR, Puliafito CA, Wong C, et al.,** Optical coherence tomography of macular holes. *Ophthalmology* 1995;102:748-756.
27. **Huang D, Kaiser PK, Lowder CY, Traboulsi EI.** Optical coherence tomography. *Retinal imaging, Mo: Mosby,* 2006:47-64.
28. **Huang D, Swanson EA, Lin CP, et al.,** Optical coherence tomography *Science.* 1991;254:1 178-1181.
29. **Ip MS, Baker BJ, Duker JS, et al.** Anatomical outcomes of surgery for idiopathic macular hole is determined by Optical Coherence Tomography. *Arch Ophthalmol* 2002; 20:29-35.

30. **Iturralde D, Spaide R F, Meyerle et al.** Intravitreal Bevacizumab (Avastin) treatment of macular edema in patients in central retinal vein occlusion, a short-term study. *Retina* 2006; 26:279-284.
31. **Izatt JA, Hee MR, Swanson EA, et al.** Micrometer -scale resolution imaging of the anterior eye in vivo with optical coherence tomography. *Arch Ophthalmol.* 1994; 112: 1584-1589.
32. **Jaffe GJ, Cahill MT.** Cystoid macular edema, In *Retinal imaging*, Mo: Mosby, 2006: 206- 218.
33. **Johnson MW, Van Newkirk MR, Meyer KA.** Perifoveal vitreous detachment is the primary pathogenic event in idiopathic macular hole- formation. *Arch Ophthalmol* 2001; 119: 215 – 22.
34. **Kaiser PK, Riemann CD, Cears JE, Lewis H.** macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction. *Am J ophthalmolo.* 2001;131:44-49.
35. **Kamel M, Hisatomi T, Ishibashi T, Tano Y.** Epiretinal membrane. In: *Retinal imaging*, Mo: Mosby, 2006:191-197.
36. **Kanski JJ.** Acquired macular disorders. In: *Clinical Ophthalmology – A Systematic Approach*. Butterworth – Heinemann, Boston. 2007; 6th ed , Ch 17, 628 – 662.

37. **Kanski JJ.** Acquired macular disorders. In: Clinical Ophthalmology – A Systematic Approach. Butterworth – Heinemann, Boston. 2003; 5th ed , Ch 14, 390 – 440.
38. **Kerbs I, Binder S, Stolba U, et al.,** Reading ability and central visual field after photo dynamic therapy. *ophthalmologica* 2004; 218:158-192.
39. **Kim BY, Simth SD, Kaiser PK.** Optical coherence tomography Patterns of diabetic macular edema. *Am J ophthalmol*; 2006: 142:405-412.
40. **King L, Joshi JP, Wirostko W, Mieler WF.** Epiretinal membranes. In: Quiroz U. et al., eds. *Macular Surgery*. Philadelphia, Pa: Lippincott Williams & Wilkins, 2000: 166-178.
41. **Ko TH, Fujimoto JG, Duker JS, et al.** Ultrahigh and standard resolution OCT of Macular Hole, *Ophthalmology* 2004;111: 2033 – 2043.
42. **Lang GE.** Diabetic retinopathy. *Developments in ophthalmology*. 2007; 39:31-47.
43. **Lang GE.** Diabetische Retinopathie-Stadieneinteilung und Laserbehandlung. *Klin Monatsbl Augenheilkd* 2005; 222: R1–R1,coated from *Developments in ophthalmology*. 2007; 39:31-47.
44. **Leys A.** Central serous retinopathy. In *Retinal Imaging* Mo: Mosby, 2006;175-180.

45. **McDonald HR, Schatz H, Johnson RN.** Introduction to epiretinal membranes. In: Ryan SI. et al.. eds. Retina, 3rd ed. St Louis, Mo: Mosby, 2000;2:1819-1826.
46. **Mahgoub MM.** Intravitreal Bevacizumab (Avastin) for the Treatment of Macular Edema Associated with Central Retinal Vein Occlusion. Bulletin of ophthalmology. Egypt, 2007; 100, N. 4, P. 497 – 500.
47. **Moss SE, Klein R, Klein BE.** The 14-year incidence of visual loss In a diabetic population. Ophthalmology 1998; 105(6):998-1003.
48. **Natarajan S, Sharma S, Mehta HB.** Diagnostics in Macular Disorders, Mo: Jaypee, 2005:69.
49. **Ozdek SC, Erdine MA, Gurelik G, et al** Optical Coherence Tomographic assessment of macular edema: comparison with Fluorescein angiographic and clinical finding. Ophthalmologica 2005;219: 86–92.
50. **Panozzo G, Gusson E, Parolini B, Mercanti A.** Role of OCT in the diagnosis and follow up of diabetic macular edema. Semin Ophthalmol 2003;18:74–81.
51. **Panozzo G, Parolini B, Gusson E, et al.** Diabetic macular edema: an OCT-based classification. Semin Ophthalmol 2004;19:13–20.
52. **Park SS, Sigelman JS, Gragoudas ME.** The anatomy and cell biology of the retina. In: Tasman W and EA Jaeger EA (eds):

- Duane's Foundations of Clinical Ophthalmology. Lippincott – Raven Publishers, Philadelphia. 1996; Cd Rom ed.
53. **Pe'er J, Folberg R, Itin A, et al.** Vascular endothelial growth factor upregulation in human central retinal vein occlusion. *Ophthalmology* 1998;105:412–416.
54. **Penfold PL, Madigan MC, Gillies MC, Provis (2001a)** Immunological and aetiological aspects of macular degeneration. *Prog Ret Eye Res* 20 : 385–414.
55. **Penfold PL, Wong JG, Gyory J, Billson FA. (2001b)** Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. *Clin Exp Ophthalmol* 29 : 188–192.
56. **Puliafito CA, Hee MR, Lin CB, et al** Imaging of macular disease with optical coherence tomography. *Ophthalmol.* (1995); 102: 217-229.
57. **Puliafito CA, Hee MR, Schuman JS, Fujimoto JG.** “Principles of operation and technology” in “Optical coherence tomography of ocular diseases”. Salk Incorporated, 6900 Grove Road, Thorofare, USA. 1996; Ch.1, P.3-15.
58. **Puliafito CA, Hee MR, Schuman JS, Fujimoto JG.:** “central serous chorioretinopathy” in “Optical coherence tomography of ocular diseases”. Salk Incorporated, 6900 Grove Road, Thorofare, USA. 1996; Ch.7:163-185.

59. **Qtani T, Kishi S, Mauyama Y.** Patterns of diabetic macular edema with optical coherence tomography. *Am J Ophthalmol* 1999;127:688–693.
60. **Remington LA.** The retina. In: *Clinical Anatomy of the Visual System*. Butterworth-Heinenmann, Boston. 1998, Ch 4, 49–87.
61. **Rivellese M, George A, Sulkes D, et al.** Optical coherence tomography after laser photocoagulation for clinically significant macular edema. *Ophthalmic surgery and Laser*. Vol. 2000; 31, No. 3, P. 192-197.
62. **Rogers AH, Witkin A.** Neovascular age-related macular degeneration. In: *Retinal imaging*, Mo: Mosby, 2006:152–63.
63. **Rosenfeld PJ, Fung AE, Puliafito CA.** Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. *Ophthalmic Surg Lasers Imaging* 2005; 36: 336–339.
64. **Salinas-Alaman A, Garcia-Layana A, Maldonado MJ, et al.** Using optical coherence tomography to monitor photodynamic therapy age-related macular degeneration. *Am ophthalmol* 2005; 140:23–28.
65. **Sarks SH, Sarks IP.** Age-related maculopathy: Nonneovascular age related macular degeneration and the evolution of geographic atrophy. In: *Ryan SL. Schachat AP, eds. Retina*. St Louis, Mo: Mosby. 2001: 1064–1099.

66. **Schatz H, Madeira D, Johnson RN, McDoland HR.** Central serous chorioretinopathy occurring in patients 60 years of age and older. *Ophthalmology* 1992; 99:63-7.
67. **Schubert HD.** Topographic anatomy of the central retina and segmental choroidal circulation – Morphology and physiology of the choroid. In: Yannuzzi LA, Flower RW and Slakter JS (eds): *Indocyanine green angiography*. CV Mosby, St Louis. 1997; part I, section A-A, Ch 2, 18 – 23.
68. **Schubert HD.** Structure and function of the neural retina – Anatomy and physiology – Retina and vitreous. In: Yanoff M and Duker JS (eds): *Ophthalmology text book*. CV Mosby, London. 1999; section 8, Ch 1, 1– 4.
69. **Seddon IM.** Epidemiology of age related macular degeneration. In; Ryan SL, Schachat AP, eds. *Retina*. St Louis, Mo: Mosby, 2001:1039-1050.
70. **Spaide RF, Iranmanesh R.** Macular Holes. In *Retinal imaging*, Mo: Mosby, 2006:181-190.
71. **Stern H.** Indication and application of OCT in cystoid Macular edema. In: *The highlights of ophthalmology 2007*; Volume 35, Number 1:16-17.
72. **Stern H.** OCT application in the evaluation of lamellar macular holes. In: *The highlights of ophthalmology 2006*; Volume 34, Number 5:20.

73. **Traboulsi EI.** In; Retinal Imaging, Mo: Mobsy, 2006: 198-205.
74. **Ufret-Vincenty RL, Lerner LE, Kaiser PK.** Non-Neovascular age-related macular degeneration. In: Retinal Imaging, Mo: Mosby, 2006: 145-151.
75. **Voo I, Elias C, Mavrofrides, et al.** Clinical applications of optical coherence tomography for the diagnosis and management of macular diseases, ophthalmology clinics of north America 17 (2004) 21-31.
76. **Yang CS, Cheng CY, Lee FL, et al** Quantitative assessment of retinal thickness in diabetic patients with and without clinically significant macular edema using optical coherence tomography. Acta Ophthalmol Scand 2001; 79:266–270.
77. **Yanoff M, Duker JS.** Retina and vitreous. In: Ophthalmology text book. CV Mosby, London. 1999; section 8.